CCCC
C4 Therapeutics Inc
2.90$
+1.1%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 244.6% | 244.6% | 241.4% | 195.1% | 239.3% | 183.7% | 283.4% | 247.3% | 276.4% | 238.1% | 285.9% | 132.2% | 342.3% | 226.4% | 439.2% | 1,074.0% | 772.6% | 74.7% | 18.0% | 51.9% | 66.7% | 17.0% | 13.4% | 34.1% | 27.8% | 32.2% | – | 16.4% | 29.3% | – | – | |
| -144.6% | -144.6% | -141.4% | -95.1% | -139.3% | 100.0% | 100.0% | -147.3% | -176.4% | -138.1% | -185.9% | -32.2% | -242.3% | -126.4% | -339.2% | -974.0% | -672.6% | 100.0% | 82.0% | 48.1% | 100.0% | 83.0% | 86.6% | 65.9% | 100.0% | 100.0% | 100.0% | 100.0% | 70.7% | 100.0% | 94.9% | |
| 244.6% | 320.9% | 233.5% | 195.1% | 239.3% | 183.7% | 283.4% | 247.3% | 276.4% | 238.1% | 285.9% | 132.2% | 342.3% | 226.4% | 439.2% | 1,074.0% | 772.6% | 1,123.3% | 256.0% | 932.0% | 741.5% | 197.8% | 207.3% | 628.0% | 374.0% | 405.3% | 231.4% | 226.8% | 400.0% | 368.5% | 285.5% | |
| 47.0% | 47.0% | 45.1% | 32.8% | 41.7% | 28.6% | 33.9% | 81.5% | 99.8% | 88.0% | 99.4% | 43.7% | 167.5% | 71.5% | 141.8% | 367.7% | 291.2% | 386.9% | 95.1% | 315.8% | 338.5% | 80.8% | 76.6% | 200.4% | 128.9% | 135.6% | 79.4% | 83.3% | 151.7% | 129.4% | 102.8% | |
| 43.2% | 375.5% | 273.2% | 32.8% | 41.7% | 212.3% | 317.2% | 81.5% | 376.2% | 88.0% | 99.4% | 43.7% | 167.5% | 71.5% | 141.8% | 367.7% | 291.2% | 1,510.2% | 333.1% | 1,195.9% | 1,160.2% | 261.6% | 270.5% | 794.3% | 502.9% | 541.0% | 406.4% | 310.1% | 522.4% | 497.9% | 413.8% | |
| -191.5% | -191.5% | -186.4% | -127.9% | -181.0% | -112.3% | -217.2% | -228.8% | -552.6% | -226.1% | -285.3% | -76.0% | -409.8% | -197.9% | -481.0% | -1,341.7% | -963.8% | -1,410.2% | -251.2% | -1,147.7% | -1,060.2% | -178.6% | -183.9% | -728.4% | -402.9% | -441.0% | -306.4% | -210.1% | -451.6% | -397.9% | -319.0% | |
| – | – | – | – | 3.8% | 1.3% | 6.7% | 10.0% | 7.2% | 5.4% | 6.3% | 2.7% | 6.9% | 3.9% | 8.2% | 21.1% | 16.1% | 22.5% | 1.5% | 74.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| -175.9% | -175.9% | -176.1% | -120.9% | -172.3% | -113.4% | -260.5% | -262.3% | -282.4% | -230.9% | -290.4% | -78.0% | -413.1% | -198.1% | -473.2% | -1,302.9% | -925.2% | -1,348.4% | -235.1% | -1,057.3% | -933.2% | -147.6% | -160.6% | -665.3% | -363.7% | -402.6% | -286.4% | -184.9% | -408.5% | -355.9% | -289.1% | |
| 3.2% | 3.2% | 12.1% | 1.2% | 2.5% | -1.7% | -2.0% | 1.5% | 1.0% | 0.7% | 1.3% | 2.7% | 3.3% | 0.2% | -7.8% | -38.8% | -22.4% | 67.1% | 9.1% | 8.5% | -66.7% | -17.0% | -13.4% | 2.5% | – | – | – | 1.1% | – | – | – | |
| -232.9% | -232.9% | -188.2% | -122.1% | -174.8% | -111.6% | -258.5% | -263.8% | -282.4% | -230.9% | -290.4% | -78.0% | -413.1% | -198.1% | -473.2% | -1,302.9% | -925.2% | -1,348.4% | -244.2% | -1,065.7% | -933.2% | -147.6% | -160.6% | -667.8% | -363.7% | -402.6% | -286.4% | -186.0% | -408.5% | -355.9% | -289.4% | |
| -181.9% | -181.9% | -178.6% | -122.8% | -174.9% | -107.7% | -248.8% | -224.4% | -270.1% | -221.4% | -280.2% | -73.7% | -402.2% | -191.1% | -458.8% | -1,263.6% | -894.6% | -1,308.7% | -215.6% | -1,005.4% | -965.3% | -130.5% | -147.2% | -631.2% | -357.4% | -393.1% | -282.3% | -181.0% | -379.2% | -351.5% | -280.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.